Atacicept: targeting B cells in multiple sclerosis (Q24628925)

Therapeutic advances in neurological disorders

Europe PubMed Central

title

Atacicept: targeting B cells in multiple sclerosis (English)

0 references

0 references

1

0 references

Bernd C Kieseier

series ordinal

2

object named as

Bernd C Kieseier

0 references

language of work or name

English

0 references

publication date

July 2010

0 references

published in

1 reference

BAFF is produced by astrocytes and up-regulated in multiple sclerosis lesions and primary central nervous system lymphoma

volume

3

0 references

issue

4

0 references

page(s)

205-16

0 references

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002656

TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002656

BAFF, a novel ligand of the tumor necrosis factor family, stimulates B cell growth

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002656

Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002656

B-cell depletion with rituximab in relapsing-remitting multiple sclerosis

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002656

The immunopathology of multiple sclerosis: an overview

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002656

TACI is mutant in common variable immunodeficiency and IgA deficiency

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002656

APRIL-deficient mice have normal immune system development

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002656

BLyS and APRIL form biologically active heterotrimers that are expressed in patients with systemic immune-based rheumatic diseases

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002656

BAFF-R, a newly identified TNF receptor that specifically interacts with BAFF

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002656

Interaction of the TNF homologues BLyS and APRIL with the TNF receptor homologues BCMA and TACI

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002656

Disruption of the interaction of T cells with antigen-presenting cells by the active leflunomide metabolite teriflunomide: Involvement of impaired integrin activation and immunologic synapse formation

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002656

Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002656

Environmental factors and their timing in adult-onset multiple sclerosis

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002656

Mechanism of action of oral fingolimod (FTY720) in multiple sclerosis

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002656

FTY720 (fingolimod) in Multiple Sclerosis: therapeutic effects in the immune and the central nervous system

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002656

Pharmacokinetics and immunoglobulin response of subcutaneous and intravenous atacicept in patients with systemic lupus erythematosus

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002656

An exploratory dose-escalating study investigating the safety, tolerability, pharmacokinetics and pharmacodynamics of intravenous atacicept in patients with systemic lupus erythematosus

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002656

Alemtuzumab vs. interferon beta-1a in early multiple sclerosis

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002656

B cells and multiple sclerosis

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002656

B lymphocytes--chief players and therapeutic targets in autoimmune diseases.

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002656

B-cell-targeted treatment for multiple sclerosis: mechanism of action and clinical data

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002656

Rituximab-induced B cell depletion in autoimmune diseases: potential effects on T cells.

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002656

Pharmacokinetics and biological activity of atacicept in patients with rheumatoid arthritis

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002656

Toward the development of rational therapies in multiple sclerosis: what is on the horizon?

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002656

Retinal nerve fiber layer is associated with brain atrophy in multiple sclerosis

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002656

Fingolimod: a novel immunosuppressant for multiple sclerosis

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002656

Rationale for cytotoxic monoclonal antibodies in MS.

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002656

The role of CD4 T cells in the pathogenesis of multiple sclerosis

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002656

Antigen specificity of clonally expanded and receptor edited cerebrospinal fluid B cells from patients with relapsing remitting MS

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002656

A proliferation-inducing ligand (APRIL) is expressed by astrocytes and is increased in multiple sclerosis

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002656

Optical coherence tomography in multiple sclerosis

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002656

Immunopathologic role of B lymphocytes in rheumatoid arthritis: rationale of B cell-directed therapy

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002656

Rituximab reduces B cells and T cells in cerebrospinal fluid of multiple sclerosis patients

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002656

Therapeutic B cell depletion and regeneration in rheumatoid arthritis: emerging patterns and paradigms

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002656

Emerging monoclonal antibody therapies for multiple sclerosis

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002656

The role of CD8+ T-cells in lesion formation and axonal dysfunction in multiple sclerosis

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002656

The role of CD4+ T-cells in the development of MS.

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002656

The B cell response in multiple sclerosis

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002656

Intrathecal IgM production at clinical onset correlates with a more severe disease course in multiple sclerosis

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002656

An APRIL to remember: novel TNF ligands as therapeutic targets

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002656

The multiple sclerosis trait and the development of multiple sclerosis: genetic vulnerability and environmental effect

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002656

Mechanisms of action for treatments in multiple sclerosis: Does a heterogeneous disease demand a multi-targeted therapeutic approach?

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002656

The role of BAFF in immune function and implications for autoimmunity

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002656

Intrathecal synthesis of oligoclonal IgM against myelin lipids predicts an aggressive disease course in MS.

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002656

TACI and BAFF-R mediate isotype switching in B cells

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002656

Environmental risk factors in multiple sclerosis aetiology

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002656

B cells in human and murine systemic lupus erythematosus

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002656

Autoimmune concepts of multiple sclerosis as a basis for selective immunotherapy: from pipe dreams to (therapeutic) pipelines

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002656

Recapitulation of B cell differentiation in the central nervous system of patients with multiple sclerosis.

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002656

The role of the BAFF/APRIL system in B cell homeostasis and lymphoid cancers

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002656

Twin concordance and sibling recurrence rates in multiple sclerosis.

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002656

Loss of TACI causes fatal lymphoproliferation and autoimmunity, establishing TACI as an inhibitory BLyS receptor

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002656

HLA-DR2 dose effect on susceptibility to multiple sclerosis and influence on disease course

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002656

New concepts in the immunopathogenesis of multiple sclerosis

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002656

Attenuation of apoptosis underlies B lymphocyte stimulator enhancement of humoral immune response

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002656

Multiple sclerosis and chronic autoimmune encephalomyelitis: a comparative quantitative study of axonal injury in active, inactive, and remyelinated lesions

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002656

The role of B cells and autoantibodies in multiple sclerosis

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002656

A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease.

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002656

Mice transgenic for BAFF develop lymphocytic disorders along with autoimmune manifestations

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002656

Reduced B lymphocyte and immunoglobulin levels after atacicept treatment in patients with systemic lupus erythematosus: results of a multicenter, phase Ib, double-blind, placebo-controlled, dose-escalating trial

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002656

Transection of major histocompatibility complex class I-induced neurites by cytotoxic T lymphocytes

30 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3002656

Cutting edge: the dependence of plasma cells and independence of memory B cells on BAFF and APRIL.

30 May 2018

1 reference

https://api.crossref.org/works/10.1177%2F1756285610371146

Short-lived plasma blasts are the main B cell effector subset during the course of multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1756285610371146

Relation of visual function to retinal nerve fiber layer thickness in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1756285610371146

Ocrelizumab, a humanized anti-CD20 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: a phase I/II randomized, blinded, placebo-controlled, dose-ranging study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1756285610371146

Cutting edge: BLyS enables survival of transitional and mature B cells through distinct mediators.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1756285610371146

A BAFF antagonist suppresses experimental autoimmune encephalomyelitis by targeting cell-mediated and humoral immune responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1756285610371146

Activated human T cells, B cells, and monocytes produce brain-derived neurotrophic factor in vitro and in inflammatory brain lesions: a neuroprotective role of inflammation?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1756285610371146

Triosephosphate isomerase- and glyceraldehyde-3-phosphate dehydrogenase-reactive autoantibodies in the cerebrospinal fluid of patients with multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1756285610371146

Chemokines in multiple sclerosis: CXCL12 and CXCL13 up-regulation is differentially linked to CNS immune cell recruitment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1756285610371146

Meningeal B-cell follicles in secondary progressive multiple sclerosis associate with early onset of disease and severe cortical pathology.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1756285610371146

Safety, pharmacokinetics and pharmacodynamics of atacicept in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1756285610371146

Intrathecal B-cell clonal expansion, an early sign of humoral immunity, in the cerebrospinal fluid of patients with clinically isolated syndrome suggestive of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1756285610371146

Detection of ectopic B-cell follicles with germinal centers in the meninges of patients with secondary progressive multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1756285610371146

Long-term B-lymphocyte depletion with rituximab in patients with relapsing-remitting multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1756285610371146

Expression of B-cell-activating factor of the TNF family (BAFF) and its receptors in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1756285610371146

Increased levels of APRIL (a proliferation-inducing ligand) mRNA in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1756285610371146

Vesicular removal by oligodendrocytes of membrane attack complexes formed by activated complement

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1756285610371146

Revised criteria for neuromyelitis optica--a new diagnostic standard?

21 January 2018

1 reference

12 December 2020

Atacicept in patients with rheumatoid arthritis: results of a multicenter, phase Ib, double-blind, placebo-controlled, dose-escalating, single- and repeated-dose study

1 reference

12 December 2020

Nonclinical safety, pharmacokinetics, and pharmacodynamics of atacicept

1 reference

12 December 2020

Multiple sclerosis: capping of surface immunoglobulin G on macrophages engaged in myelin breakdown

1 reference

12 December 2020

The ups and downs of multiple sclerosis therapeutics

1 reference

12 December 2020

A comparative analysis of B cell-mediated myelin oligodendrocyte glycoprotein-experimental autoimmune encephalomyelitis pathogenesis in B cell-deficient mice reveals an effect on demyelination

1 reference

12 December 2020

Activation and accumulation of B cells in TACI-deficient mice

1 reference

12 December 2020

Immunology of multiple sclerosis

1 reference

12 December 2020

TACI-Ig neutralizes molecules critical for B cell development and autoimmune disease. impaired B cell maturation in mice lacking BLyS

1 reference

12 December 2020